“While we anxiously wait for more affordable generic versions of bedaquiline to become available, we want to urge governments to make sure people with drug-resistant TB get the best possible treatment,” says Lara Dovifat, Campaigns and Advocacy Advisor at MSF’s Access Campaign. “Today’s price reduction is a helpful step.”
MSF has been involved in TB care for 30 years, and is the largest non-governmental provider of TB treatment worldwide. MSF teams work alongside national health authorities to treat patients in a wide variety of settings, including rural regions, chronic conflict zones, urban slums, prisons, and refugee camps.
In 2018, an estimated 484,000 people developed drug-resistant TB globally, but only 32 per cent were able to access treatment. MSF continues to call on Johnson & Johnson to further reduce the price of bedaquiline, and to offer this lower price to all countries with a high drug-resistant TB burden.